Triphase Accelerator Corp., a private drug development accelerator with offices in San Diego and Toronto, announced preclinical study results demonstrating that the combination of marizomib, Triphase’s highly-differentiated proteasome inhibitor, and pomalidomide (Pomalyst) was synergistic in killing multiple myeloma cells.
“Patients with relapsed and refractory multiple myeloma urgently need new options to treat this otherwise fatal hematologic cancer,” said Paul Richardson, the lead clinical investigator of the marizomib study group and director of clinical research at Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute. “These preclinical findings are especially promising because they demonstrate the potent activity of marizomib when combined with pomalidomide, and add to the growing body of evidence that marizomib is potentially very active against resistant multiple myeloma.”
Triphase is currently evaluating marizomib in a Phase 1 study in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma. Marizomib is also being evaluated in an ongoing Phase 2 clinical trial in combination with dexamethasone in a highly refractory multiple myeloma population, including patients refractory to carfilzomib.